Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
With over three decades of preclinical research behind it, BPC-157 remains one of the most actively studied peptides in tissue repair science
The corresponding pharmacokinetic parameters are listed as follows: T max = 0.167 h, C max = 155 11.8 ng Eq./ml, AUC 0t = 4945 417 h ng Eq./ml, AUC 0 = 12956 2074 hng Eq./ml, average residence time (MRT 0-t ) of plasma total radioactivity = 33.2 1.03 h, and t 1/2 = 102 h (Table 9)
European Neurology (1987) 6
BPC-157 for Dogs: Key Potential Benefits Joint inflammation: May reduce swelling and stiffness in arthritic joints Tissue repair: Promotes healing of tendons, ligaments, and cartilage Recovery speed: May shorten recovery time after surgery or injury Nerve health: Shows protective effects on nerve tissue in animal studies GI healing: May support dogs with IBD, leaky gut, or chronic digestive issues Pain reduction: Reported pain relief without immune suppression Note: Most evidence comes from animal studies
Reported benefits (per available research): Studied for restoring more youthful pulsatile GH and IGF-1 secretion in older adults, based on a small 1997 randomized, placebo-controlled human trial of a closely related GHRH(1-29) analog published in the Journal of Clinical Endocrinology & Metabolism May support gains in lean body mass in men specifically: that same 16-week trial found a statistically significant increase in lean body mass in men but not in women, alongside a significant increase in skin thickness (a marker of dermal collagen) in both sexes Proposed to support broader recovery and body-composition goals tied to growth-hormone-axis activity, though sermorelin-specific modern adult trial data remains thin, and much of the anti-aging and muscle-building framing used in commercial marketing outpaces the current clinical evidence base Known risks and side effects: Injection-site reactions (pain, swelling, or redness) are the most commonly reported adverse event associated with sermorelin therapy in manufacturer drug-labeling data Headache, flushing, dizziness, difficulty swallowing, hyperactivity, drowsiness, and hives have also been reported less commonly per that same labeling data
